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PURPOSE: To evaluate alanine aminotransferase levels before and after a hemodialysis session and to correlate these values with 
the hematocrit rate and weight loss during hemodialysis.
PATIENTS AND METHODS: The serum alanine aminotransferase levels, hematocrit rate and body weight were measured and 
correlated before and after a single hemodialysis session for 146 patients with chronic renal failure. An receiver operating charac-
teristic (ROC) curve for the serum alanine aminotransferase levels collected before and after hemodialysis was plotted to identify 
hepatitis C virus-infected patients.
RESULTS: The mean weight loss of the 146 patients during hemodialysis was 5.3% (p < 0.001). The mean alanine aminotrans-
ferase levels before and after hemodialysis were 18.8 and 23.9 IU/, respectively, denoting a significant 28.1% increase. An equally 
significant increase of 16.4% in the hematocrit rate also occurred after hemodialysis. The weight loss was inversely correlated with 
the rise in both the alanine aminotransferase level (r = 0.3; p < 0.001) and hematocrit rate (r = 0.5; p < 0.001). A direct correlation 
was found between the rise in alanine aminotransferase levels and the hematocrit during the hemodialysis session (r = 0.4; p < 
0.001). Based on the ROC curve, the upper limit of the normal alanine aminotransferase level should be reduced by 40% relative 
to the upper limit of normal if the blood samples are collected before the hemodialysis session or by 60% if blood samples are 
collected after the session.
CONCLUSION: In the present study, significant elevations in the serum alanine aminotransferase levels and hematocrit rates 
occurred in parallel to a reduction in body weight after the hemodialysis session. These findings suggest that one of the factors for 
low alanine aminotransferase levels prior to hemodialysis could be hemodilution in patients with chronic renal failure.
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INTRODUCTION
The frequency of raised serum alanine aminotransferase 
(ALT) concentrations in patients who are infected with 
the hepatitis C virus (HCV) and have chronic renal failure 
(CRF) that requires hemodialysis (HD) therapy has been 
reported to be between 4 and 67%.1-3 On the other hand, 
between 54 and 75% of patients with HCV antibodies (anti-
HCV) without CRF have increased ALT levels.4 On the basis 
of these considerations, the ALT levels are assumed to be 
poor predictors of hepatocellular damage in the chronic HD 
population.1, 2
A number of factors may explain the reduction in the 
ALT levels in HD patients, such as low or fluctuating serum 
viral load due to adsorption in the dialyzer membrane; non-
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virulent HCV strains; intermittent increases in the serum 
ALT concentration; or decreased levels of vitamin B6, a 
coenzyme of ALT.5-8 The ALT levels may also be lower 
before the HD session due to hemodilution and may increase 
after the session, depending on how much liquid is lost 
during dialysis.
Other studies have found that the ALT levels – even those 
not exceeding the upper limit of normal (ULN) – are higher 
in the anti-HCV positive patients in comparison to the anti-
HCV negative patients. Indeed, new criteria for the ULN of 
the ALT have been proposed for patients on HD.5, 7, 9
A new ULN for the serum levels of ALT has also been 
proposed, corresponding to around 70% of the present ULN, 
for screening for liver damage not only in patients with CRF 
but also for the general population. One argument for this 
decrease is that sub-clinical conditions such as fatty liver 
disease and HCV infection had not yet been identified when 
the last ULN was established about 20 years ago. With the 
new ULN criteria, the ALT sensitivity should improve from 
55 to 76% for the detection of patients with minimal to mild 
histological lesions, despite a reduction in specificity from 
97 to 89%.9 Recently, a population-based study carried out in 
Korea revealed that the risk of death from liver disease was 
higher among patients with ALT levels closer to the ULN 
in comparison to patients with lower ALT levels. Thus, a 
reduction to below 75% of the current normal cutoff values 
was suggested.11
Likewise, in trials using peginterferon and ribavirin for 
the treatment of patients with HCV infection and “normal” 
ALT concentrations, cases with a sustained virological 
response exhibited a greater decrease in ALT values than 
cases that did not respond. These results suggest that, in 
this group of patients, the “normal” ALT levels before 
therapy may be higher than in individuals without chronic 
hepatitis and that viremia clearance after treatment induces 
a subsequent reduction towards “true normal” ALT levels.12 
Considering the clinical importance of these differences in 
ALT normality, a reduction of approximately 30% has been 
suggested for the conventional ULN serum ALT levels.13
The aim of the present study was to evaluate the ALT 
levels in patients with CRF and correlate those values with 
the hematocrit rate and weight loss before and after a single 
HD session. On the basis of these data, a more appropriate 
ALT cutoff value was established in order to better identify 
biochemical activity due to HCV infection in HD patients 
with CRF.
PATIENTS AND METHODS
In a dialysis unit in northeastern Brazil, 146 patients with 
CRF undergoing HD treatment were studied after giving 
informed consent. All patients over 16 years of age who fulfilled 
the following criteria were included: regular hemodialysis for 
at least 6 months and no history of alcohol intake (> 40 g/
day). The study protocol was approved by the Research Ethics 
Committee of the University Federal de Pernambuco (Brazil).
The serum ALT was determined by an automated kinetic 
method (Abbott®) in blood samples that were obtained 
immediately prior to and at the end of a single HD session. 
The serum concentration for each patient was divided by the 
ULN of the ALT according to gender (40 IU/L for women and 
43 IU/L for men). The hematocrit rate was determined before 
and after the same HD session using a CELL-DYN 4000 
analyzer. The antibody against hepatitis C virus (anti-HCV), 
hepatitis B virus surface antigen (HBsAg) and antibody 
against hepatitis B virus surface antigen (anti-HBs) levels 
were determined through enzyme immunoassays (Abbott®).
For each analyzed variable, differences before and 
after the HD session were established as a gradient (after 
– before).
The statistical analysis was carried out using SPSS v8.0. 
The chi-squared test was used to determine the frequency 
difference, and Student’s t-test was used to evaluate the 
mean differences. The degree of correlation between 
measurements before and after the HD session was assessed 
using the Pearson’s correlation test. A significance level of 
p < 0.05 was chosen.
The best cutoff value for the ALT was established from 
a receiver operating characteristic (ROC) curve, which is 
the value that maximizes the sum of the sensitivity and 
specificity to identify the biochemical activity in HD patients 
with HCV antibodies.
RESULTS
Among the 146 patients, 88 (60%) were men and 58 
(40%) were women; the average age was 48 ± 15 years 
(range 16-84 years). HCV antibodies were detected in 
13 (8.9%) patients; 11 patients (7.5%) tested positive for 
HBsAg; and 95 patients (65%) tested positive for anti-HBs.
The mean patient weight was 62.4 ± 13.8 kg (range 37-
119 kg) before the HD session and 59.2 ± 13.3 kg (range 
36-113 kg) after the session. The mean weight reduction was 
3.3 ± 1.3 kg (p < 0.001), denoting a 5.3% loss during each 
session (range 0-12.5%).
The mean serum ALT levels before and after the HD 
session were 18.8 ± 16.3 IU/L and 23.9 ± 20.2 IU/L, 
respectively, denoting an increase of 5.1 IU/L or 28.1% (p < 
0.001). The mean hematocrit rates before and after the HD 
were 32.4% ± 4.7 and 37.7% ± 6.1, respectively, denoting 
a 5.3% increase in the hematocrit rate (p < 0.001). This 
corresponded to an increase of 16.4% (Figure 1).
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At the end of the HD session, 137 of the 146 patients 
(94%) had raised ALT levels; on the other hand, 6 patients 
(4%) maintained the same level, and 3 patients (2%) had 
decreased levels. Regarding the hematocrit rates, 137 (94%) 
patients had an increased hematocrit rate after the HD 
session; meanwhile, 4 patients (2.7%) maintained their rate, 
and the rate dropped in 5 patients (3.4%). Only one patient 
maintained the same body weight, in the other 145 patients 
(99.3%) the weight dropped at the end of the HD session.
The weight loss that occurred throughout the HD session 
exhibited an inverse correlation with the increase in both the 
ALT serum levels (r = 0.3; p < 0.001) and the hematocrit rate 
(r = 0.5; p < 0.001). A direct correlation was found for the 
parallel increase in the ALT and hematocrit rate (r = 0.4; p < 
0.001) throughout the HD session (Figure 2).
To determine the ROC curves for the mean ALT values 
before and after the HD session, the 11 HBsAg-positive 
patients were excluded from the analysis (one of these 
was also anti-HCV positive). Among the 135 remaining 
patients, 80 (59%) were men, and the average age was 48 
years. Among the 123 anti-HCV-negative patients, 6 (4.9%) 
exhibited high ALT levels before the HD session; among 
the 12 anti-HCV positive patients, only 1 (8.3%) exhibited 
high ALT levels before the HD session (p = 0.86). After the 
HD session, 9 (7.3%) of the 123 anti-HCV negative patients 
had higher ALT levels, and 2 (16.6%) of the 12 anti-HCV-
positive patients had higher ALT levels (p = 0.56).
Among the 12 anti-HCV-positive patients, the mean ALT 
divided by the ULN (ALT/ULN) before and after the HD 
session was 0.54 ± 0.29 and 0.67 ± 0.34, respectively (p = 
0.32). Among the 123 anti-HCV-negative patients, the ALT/
ULN before and after the HD session was 0.44 ± 0.39 and 
0.56 ± 0.48, respectively (p = 0.03).
The best serum ALT concentration cutoff value for 
identifying biochemical activity in the anti-HCV positive 
patients before the HD session was 0.40, or 40% of the 
ULN. This value corresponded to 75% sensitivity, 59% 
specificity, and positive and negative predictive values of 15 
and 96%, respectively. After the HD session, the best serum 
ALT concentration cutoff value for identifying biochemical 
activity in the anti-HCV positive patients was 0.60, or 60% 
of the ULN. This value corresponded to 66% sensitivity, 
65% specificity, and positive and negative predictive values 
of 16 and 95%, respectively.
In clinical practice, we recommend that the ULN for 
women decreases from 40 IU/L to 16 IU/L if the ALT was 
collected before the HD session or to 24 IU/L if the ALT was 
collected after the HD session. For men, the ULN of the ALT 
would then decrease from 43 IU/L to 17 IU/L if collected 
before the HD session or to 28 IU/L if collected after the 
HD session (Table 1).
Table 1 - Mean body weight (kg), serum levels of alanine 
aminotransferase (IU/L), and hematocrit rate (%) measured 
before and after a hemodialysis session in 146 patients with 
chronic renal failure at Recife, PE, Brazil
Hemodialysis session p
Before After
Body weight (kg) 62.4 ± 13.8 59.2 ± 13.3 0.001
Alanine 
aminotransferase (IU/L)
18.8 ± 16.3 23.9 ± 20.2 0.001
Hematocrit rate (%) 32.4 ± 4.7 37.7 ± 6.1 0.001
Figure 1 - Mean body weight (p < 0.001), hematocrit rate (p < 0.001) and 
serum levels of alanine aminotransferase (ALT; p < 0.001) measured before 
and after a hemodialysis session in 146 patients with chronic renal failure, 
Recife, PE, Brazil
Figure 2 - Correlation between the serum alanine aminotransferase gradient 
and hematocrit rate gradient before and after a hemodialysis session in 146 
patients with chronic renal failure, Recife, PE, Brazil
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DISCUSSION
The serum ALT concentration is lower in patients with 
CRF submitted for HD treatment and is a poor predictor of 
HCV infection in this population. Evaluating the laboratory 
and histological data from 92 patients with HCV-related 
liver disease (46 renal transplant candidates and 46 control 
subjects with normal renal function), Cotler et al.13 found 
that the serum ALT levels were significantly lower in patients 
with CRF. The exact reason for the lower ALT in patients 
with CRF needs to be fully elucidated. One possibility is 
due to liver cells protection by hepatocyte growth factor 
(HGF), which is higher concentration in patients with CRF 
for whom HD is recommended.14 The lower ALT activity in 
HD patients may also be a consequence of a smaller serum 
HCV viral load, due to the adsorption of the virus genome 
in the dialyzer membrane or to the induction of endogenous 
interferon caused by the HD.15 On the other hand, a recent 
article reported that HCV-infected patients with CRF 
submitted for HD have lower ALT levels, but the viral load 
and the genotype distribution are similar to those found in 
HCV-infected patients with normal renal function.16
Another hypothesis to explain the lower serum levels 
of ALT in patients with CRF could be the severity of 
the impairment of renal function induced by glomerular 
damage. In fact, Fabrizi et al.7 found significantly lower 
serum ALT activity in patients on chronic HD than in pre-
dialysis patients with CRF, and they reported a correlation 
between the reduced ALT activity and the degree of renal 
function in these patients. In a large cohort of pre-dialysis 
patients,17 the HCV-infected patients had significantly higher 
ALT levels compared to the non-infected patients, and the 
accuracy of the ALT in detecting the HCV infection was 
92%. Thus, Lemos et al.17 have suggested that the serum 
ALT level in pre-dialysis patients may be a good marker of 
HCV infection.
Hung et al.18 evaluated 90 patients on continuous 
ambulatory peritoneal dialysis (CAPD) and 526 healthy 
adults and found a mean ALT concentration of 15 IU/L in 
the CAPD patients as opposed to 22 IU/L in the control 
group (p < 0.0001). Such data support the fact that patients 
with CRF have lower levels of ALT, regardless of HD.
In the present study, the ALT levels also increased 
significantly after the HD session in both patient groups 
(with and without anti-HCV). This increase may be a 
consequence of the loss of liquid during the session, 
thereby correcting the prior hemodilution. This premise 
is reinforced by the direct correlation found between the 
ALT gradient and the hematocrit rate throughout HD and 
the inverse correlation between the ALT gradient and the 
weight loss during the HD session. Furthermore, Conway et 
al.19 evaluated the serum cardiac troponin levels in patients 
undergoing chronic HD and found that the concentration of 
this enzyme was significantly higher after the HD session as 
compared to before the session. The authors suggested that 
this rise in troponin levels following HD was probably due to 
hemoconcentration, as was also detected with the hematocrit 
rate in the same study.
The possibility that the rise in the ALT levels is due to 
hemodilution correction following the HD sessions does 
not explain the reduced ALT levels in the CAPD patients, 
who theoretically would not have hemodilution. Another 
possibility to explain the lower serum levels of ALT in 
patients with CRF could be hypotension-induced liver cell 
injury during the HD session. However, ischemic hepatitis 
is generally related to hepatocyte necrosis and these patients 
exhibits a higher serum ALT concentration than that found 
in our patients. Perhaps hemodilution also contributes to the 
reduction in the ALT levels before the session in patients with 
CRF requiring regular HD therapy. In the present study, we 
detected an approximately 25% increase in the serum ALT 
levels after the HD session, but this increase was not sufficient 
to exceed the conventional ULN value. In fact, after HD, only 
2 of the 12 patients (16.6%) with chronic HCV infection had 
ALT concentrations above the conventional ULN, thereby 
supporting the need for a lower ALT cutoff value.
In conclusion, the present study has revealed that most 
of the CRF patients submitted to chronic HD treatment had 
serum ALT concentrations below the ULN, even though 
these levels were higher than in patients on HD without 
HCV infection. The ALT levels, however, underwent a 
significant increase after the HD session, probably due to 
the correction in hemodilution, as was also observed with 
the hematocrit rate. Therefore, by reducing the ALT cutoff 
value to about 60% of the previously established value 
and collecting the blood sample after the HD session, it 
is possible to better identify patients with hepatocellular 
damage. Further studies, however, are needed in order to 
validate the reduced ULN for the serum ALT concentration 
in clinical practice.
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